Project Grant R01HL175942
- This $548,816 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Illinois to investigate the role of the SEC16B protein in regulating lipid metabolism and transport in the liver. The project aims to define how SEC16B mediates the formation of lipid droplets and very low-density lipoprotein (VLDL) secretion, which are key processes involved in cholesterol and triglyceride homeostasis. This...
- This federal Project Grant award for $603,632, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, aims to define the role of the PLA2G12B protein in regulating the assembly, plasma levels, metabolism, and cardiovascular disease risk of apolipoprotein B (apoB)-containing lipoproteins. The primary grantee, The Johns Hopkins University, will leverage novel tools to investigate how...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,102,500 in funding to the University of California, Los Angeles (UCLA) from August 2025 through April 2032. The objective of the project is to address persistent problems in intravascular triglyceride metabolism, which can lead to higher levels of atherogenic lipoproteins and increased risk of coronary heart disease. The project builds on the awardee's prior...
- This federal Project Grant award of $231,552.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Northwestern University supports research on the role of the MTCH2 gene in cardiac regulation, heart failure, and obesity. The key objectives are to investigate how reduced MTCH2 protein affects mitochondrial function and dynamics in the heart, potentially leading to cardiomyopathy and weight loss. The research involves creating a...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding research at the University of Arizona to investigate whether and how the hepatocyte protein TMEM141 regulates lipoprotein metabolism and atherosclerosis. The $744,453 award, which runs from August 1, 2025 through May 31, 2029, will utilize genetically modified mouse models and state-of-the-art techniques to study the role of TMEM141 in lipid and lipoprotein...
- This Project Grant award, valued at $748,965.00, was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Northwestern University for a research project titled "Vascular Proliferative Resilience - Summary in Adults". The project aims to investigate the dynamics, spatial context, and molecular regulators of endothelial cell proliferation in the aorta, with the goal of deciphering the mechanisms underlying the maintenance of vascular...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $706,220.00 supports research to elucidate the role of the nuclear pore protein NUP93 in regulating endothelial cell function and vascular health. The research aims to investigate how phosphorylation of NUP93 by the AKT signaling pathway impacts YAP localization and endothelial inflammation, as well as the in vivo importance of NUP93 phosphorylation in...
- This federal Project Grant award of $1,119,410.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a multi-disciplinary research initiative to investigate longitudinal changes in DNA methylation (LC-DNAM) and its relationship to cardiovascular disease (CVD) risk factors and outcomes across four large population-based cohort studies - ARIC, CARDIA, FHS, and MESA. The research aims to: 1)...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is supporting research to investigate how gut microbe-derived lipids, specifically N-acyl amides, can signal through the host receptor GPR119 to impact inflammatory and metabolic pathways related to cardiometabolic diseases like obesity and atherosclerosis. The $743,302 award to the Cleveland Clinic Lerner College of Medicine of Case Western...
This $733,000 federal Project Grant award from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by Northwestern University to characterize the full spectrum of apolipoprotein post-translational modifications (PTMs) in human plasma and quantify their associations with upstream factors like adiposity and insulin resistance, as well as downstream impacts on atherogenic lipid levels and coronary heart disease events. The research aims to advance understanding of how PTMs of apolipoproteins, which are central to cholesterol metabolism and atherosclerosis pathobiology, may mediate cardiometabolic health and cardiovascular disease outcomes. The project will run from September 2025 through June 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $733.0k | 9/12/25 |